EMBER-MDD Will Test Multi-Omic Biomarkers for Esketamine Response
TL;DR: A 2026 methodology paper in European Archives of Psychiatry and Clinical Neuroscience describes EMBER-MDD, a research-only multi-omic study designed to find treatment-resistance and esketamine-response biomarkers in about 420 adults with major depressive disorder. Key Findings About 420 adults: EMBER-MDD will analyze biomaterials from approximately 420 adults with major depressive disorder. 210 versus 210 design: …
